InVivoMAb anti-mouse/human/rat/monkey ICOS (CD278)

Stone EL, Pepper M, Katayama CD, et al. ICOS coreceptor signaling inactivates the transcription factor FOXO1 to promote Tfh cell differentiation. Immunity. 2015,42(2):239-251. doi: 10.1016/j.immuni.2015.01.017

Hasegawa M, Fujimoto M, Matsushita T, et al. Augmented ICOS expression in patients with early diffuse cutaneous systemic sclerosis. Rheumatology (Oxford). 2013,52(2):242-51. doi: 10.1093/rheumatology/kes258

Fu T, He Q, Sharma P. The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res. 2011,71(16):5445-54. doi: 10.1158/0008-5472.CAN-11-1138

Redoglia V, Dianzani U, Rojo JM, et al. Characterization of H4: a mouse T lymphocyte activation molecule functionally associated with the CD3/T cell receptor. Eur J Immunol. 1996,26(11):2781-9.